Modality
siRNA
MOA
CAR-T CD19
Target
FcRn
Pathway
JAK/STAT
Obesity
Development Pipeline
Preclinical
~Sep 2018
→ ~Dec 2019
Phase 1
Mar 2020
Phase 1Current
NCT03852518
108 pts·Obesity
2020-03→TBD·Active
108 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Trial Timeline
P1
Active
Active|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03852518 | Phase 1 | Obesity | Active | 108 | VA |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Cevizanubrutinib | Johnson & Johnson | Preclinical | FcRn | |
| RHH-1546 | Roche | Phase 2/3 | C5 | |
| Gelinaritide | AbbVie | Preclinical | FcRn | |
| Datoglumide | AbbVie | Approved | CFTR | |
| Talalemzoparlimab | Gilead Sciences | Phase 1 | FcRn | |
| GIL-2259 | Gilead Sciences | Approved | SMN2 | |
| Sovafutibatinib | Moderna | Approved | FcRn | |
| BII-4342 | Biogen | Phase 2/3 | CGRP | |
| ITC-879 | Intra-Cellular | Approved | FcRn | |
| Talasotorasib | Exelixis | Preclinical | APOC3 |